S&P 500 7,498.96 -0.14% NASDAQ 25,690.90 -0.57% DOW 52,218.58 -0.01% R2K 2,959.94 -0.92% VIX 17.70 +6.37% US 10Y 4.66 +0.63% DXY 101.22 +0.08% GOLD 4,088.20 -1.42% CRUDE 90.87 +4.65% BITCOIN 65,578.44 -0.79%
Next Bullish Trade
Sign in
TAK

Takeda Pharmaceutical Company Limited NYQ · TAK

$16.87 -0.36 (-2.09%)
Extended · +1.08σ Grade B
Mkt cap $53.9B
P/E
Day $16.84 – $17.21
52wk $14.84 – $18.90
Avg vol 3.2M
Beta 0.09
Div yld 3.65%
Next earnings 2026-07-30

Quick read

At a glance

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products.

TAK last traded at $16.87, down 2.1% on the day; that's in the middle part of its 52-week range ($14.84–$18.90). Right now it's trading above its recent average — momentum is positive, though some of the move may already be in the price.

The next scheduled earnings report (2026-07-30) is the biggest known catalyst on the calendar, and after a strong run, watch whether the price can hold its gains on quieter days.

A quick snapshot built from the data on this page — not investment advice. Always do your own research.

Today's read

Grading desk →

Price is stretched well above its normal range — a standard stretch that often pulls back toward normal.

Long
Setup score 9 / 100
Price is sitting close to its normal range — no real dip to buy yet.
Technical read: above KC1 lower, +1.02 ATR from EMA21 · no notable pattern
What it means: Price is sitting close to its normal range — no real dip to buy yet. The trigger bar shows no standout candle signal yet.
Score split: chart signals 9 / 80 · news & fundamentals checks 0 / 20 — chart signals carry most of the grade.
How this grade was earned
total 9 pts
Cycle position 6
Market fit 3

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

Short B
Setup score 40 / 100
Price is stretched well above its normal range — a standard stretch that often pulls back toward normal.
ℹ️ Stretched (KC2): stop is set a little wider to avoid a whipsaw, so the reward/risk reads a bit lower by design.
  • · KC2 upper stretch — standard mean-reversion tier
  • · RSI hook from overbought (58)
  • · Stochastic bear cross in overbought
Technical read: KC2 upper, +1.02 ATR from EMA21 · no notable pattern
What it means: Price is stretched well above its normal range — a standard stretch that often pulls back toward normal. The trigger bar shows no standout candle signal yet.
Score split: chart signals 40 / 80 · news & fundamentals checks 0 / 20 — chart signals carry most of the grade.
How this grade was earned
total 40 pts
Cycle position 22
Momentum 12
Market fit 6

Each bar shows how many points that factor added. The more points — and the more factors that agree — the higher the letter grade.

132-Day Trend Zones

Full chart →
21 EMA +1 ATR +2 ATR −2 ATR
O H L C

Key statistics

All statistics →

TAK is a $53.9 billion company, it moves more calmly than the market (beta 0.1).

Market cap $53.9B
P/E ttm
Beta 0.09
52w range $14.84 – $18.90
Avg volume 3.2M
Dividend yield 3.65%
Sector Healthcare
Next earnings 2026-07-30
52-week range · today's price
$14.84$18.90

More on TAK

Options idea

See more →
CALL $18 2026-08-21
$0.30
PUT $18 2026-08-21
$1.25

Earnings

See more →
Last reported
2023-07-27
EPS (act / est)
28.76 / 18.62
Surprise
+54.4%
Next report
2026-07-30

About

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti,…